TRAX

First Tracks Biotherapeutics, Inc.

Healthcare · Biotechnology · —

38.60$ -1.5% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Cash Flow

First Tracks Biotherapeutics, Inc. (TRAX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -143 million $. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

Tick rows to compare them in a chart (up to 4)

Cash Flow TRAX
Line item	2023	2024	2025
Operating Cash Flow	-93	-126	-143
Depreciation & Amortization	2.4	2.4	2.4
Stock-Based Compensation	18	27	32
Change in Working Capital	2.9	19	-1.5
Capital Expenditures	0.8	0.4	0.1
Investing Cash Flow	145	95	228
Financing Cash Flow	-87	118	30
Change in Cash	-35	87	115
Free Cash Flow	-94	-126	-143

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Cash Flow

Cookie settings